Gcp Ii Inhibitors Prevent Neurodegeneration

To examine the potential usefulness of GCP II inhibitors in familial amyotrophic lateral sclerosis (FALS), 2-MPPA (30 mg/kg/day po) was administered to SOD G93A mice daily from 37-39 days of age. Clinical signs were measured weekly. In mice treated with 2-MPPA there were statistically significant delays in the onset of all of the clinical end-points measured except for shaking of limbs (table below). There was also a significant prolongation in the median survival - from 190 days in the vehicle treated group to 219 days in the 2-MPPA treated group, as illustrated by the Kaplan-Meier survival curve21 (Fig. 5). The results support the use of GCP II inhibitors as potential neuroprotective agents against neurodegenerative disorders such as ALS.

Clinical Symptoms

Delay in Onset (days)

p value

Crossing of limbs

Was this article helpful?

0 0

Post a comment